Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Leading the way in novel anti-cancer research

19.11.2003


Key AstraZeneca data presented at the AACR-NCI-EORTC meeting



New research presented today at an official AACR-NCI-EORTC* press conference highlights the potential of a new approach to fighting cancer -- inhibition of Aurora kinases. The study, carried out by AstraZeneca, represents part of a body of innovative research and discovery work undertaken by the company as part of a broad based development program of novel cancer therapies. Key research presented this week also includes results from a study combining two agents developed by AstraZeneca: an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and the vascular targeting agent ZD6126.

New frontiers in cancer biology – inhibition of Aurora kinases:


The Aurora kinase family is important in regulating mitosis and cell division. Because these kinases are only expressed in cells that are actively dividing, they could be an important new target in cancer. Aurora kinases are commonly over expressed in breast, colon, pancreas and bladder tumors and this is correlated with poor prognosis in these diseases. AstraZeneca scientists have discovered selective and potent inhibitors of Aurora kinase activity that may have potential application in human cancer treatment. These inhibitors of Aurora kinase are being investigated to ascertain their potential in the treatment of cancer.

"Through cutting-edge research and development, AstraZeneca hopes to achieve a better understanding of Aurora kinases and their regulation, which could in time be a basis for treating or even preventing cancer," said George Blackledge, Vice President, Medical Director of Oncology, AstraZeneca. "This is part of a broad based development program in cell cycle directed therapies."

Leading the way in combining novel anti-cancer approaches:

New pre-clinical research presented at the meeting shows that combining a vascular targeting agent with an EGFR tyrosine kinase inhibitor may result in greater anti-tumor activity than either agent alone. These agents attack the tumor by different mechanisms.

Tumor blood vessels differ significantly from normal blood vessels. The endothelial cells which line their vessel walls retain the characteristics of immature, newly formed dividing cells and appear to depend heavily on a tubulin cytoskeleton to maintain their shape. Vascular targeting agents are designed to disrupt this cytoskeleton, causing the endothelial cells to change shape from flat to round, resulting in damage to the blood vessel lining. This causes vessel congestion and cessation of blood flow. The tumor is thus starved of oxygen and nutrients, while its waste products start to build up to toxic levels. As a result, much of the tumor dies.

The potential of ZD6126, a vascular targeting agent, and an EGFR tyrosine kinase inhibitor to work together in combination as a cancer treatment approach was evaluated in preclinical work being presented today at this meeting. Based on the results seen in these models, clinical investigation of this drug combination is about to begin.

Also presented at the meeting, University of Florida medical scientists reported the results of the combination of ZD6126 with another AstraZeneca novel anticancer agent in development known as ZD6474, an anti-angiogenesis agent. Anti-angiogenesis agents being developed by AstraZeneca are designed to block the vascular endothelial growth factor (VEGF) signaling pathway. This pathway is a critical step in angiogenesis, the process by which tumors stimulate the formation of new blood vessels. Based on results from preclinical studies, clinical investigations of the combination of vascular targeting agents and anti-angiogenesis agents are planned.

Other novel approaches:

AstraZeneca has a broad portfolio of novel cancer agents in early development for the potential treatment of a wide range of tumors. New pre-clinical data on several AstraZeneca novel agents have been presented at the AACR/NCI/EORTC meeting in Boston this week:
  • An oral prenylation inhibitor treatment that prevents the activation of a number of growth promoting proteins and thus prevents cancer cells from dividing (proliferating)
  • An orally active Src kinase inhibitor, which reduces the ability of cancer cells to invade normal tissues, preventing tumors from spreading
  • CDK (cyclin dependent kinase) and Aurora kinase inhibitors, which interfere with crucial steps in cell division and inhibit the proliferation of cancer cells

About AstraZeneca:

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. In the United States, AstraZeneca is a $9.3 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

For more information about AstraZeneca, please visit www.astrazeneca-us.com

*AACR: American Association for Cancer Research; NCI: National Cancer Institute; EORTC: European Organization for Research and Treatment of Cancer.

Emily Denney | EurekAlert!
Further information:
http://www.astrazeneca.com/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

HLF: From an experiment to an establishment

29.09.2016 | Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

Laser use for neurosurgery and biofabrication - LaserForum 2016 focuses on medical technology

27.09.2016 | Event News

 
Latest News

New Multiferroic Materials from Building Blocks

29.09.2016 | Materials Sciences

Silicon Fluorescent Material Developed Enabling Observations under a Bright “Biological Optical Window”

29.09.2016 | Materials Sciences

X-shape Bio-inspired Structures

29.09.2016 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>